United States News All stories

ICL (NYSE:ICL) has announced a definitive agreement to acquire Bartek Ingredients, a global leader in food-grade malic and fumaric acid.

The acquisition will significantly enhance ICL’s portfolio in the specialty food solutions sector, as Bartek’s products are used across a range of applications in the food, beverage, confectionery, and bakery industries.

OpenGate Capital, a global private equity firm, has completed the sale of ScioTeq, a leader in ruggedized display systems for the aviation and defense industries, to the aerospace and defense fund of global alternative asset manager Tikehau Capital.

CarMax (NYSE:KMX) reported mixed third-quarter results for the period ending November 30, 2025.

Retail used unit sales decreased by 8%, and comparable store used unit sales dropped 9%.

FactSet (NYSE:FDS) reported solid first-quarter results for fiscal 2026, with GAAP revenues rising 6.9% year-over-year to $607.6 million, and organic revenues increasing 6% to $600 million.

Optical Cable Corporation (NASDAQ:OCC) today reported strong results for fiscal 2025, showing a significant improvement in profitability despite a slight dip in net sales.

For the year ended October 31, 2025, the company saw gross profit rise by 24.1%, reaching $22.6 million, and gross margin increase to 30.9% from 27.3% in fiscal 2024.

Trump Media & Technology Group (NASDAQ:DJT) and TAE Technologies have announced a landmark merger valued at over $6 billion, positioning the combined entity as one of the first publicly traded companies in the burgeoning fusion energy sector.

Uxin (NASDAQ:UXIN), a leading Chinese online used car platform, announced impressive financial results for the third quarter of fiscal 2025, reporting a substantial 76.8% year-over-year increase in total revenue.

The European Medicines Agency (EMA) has officially validated the marketing authorization application for DATROWAY® (datopotamab deruxtecan), a novel antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not eligible for PD-1/PD-L1 inhibitors.

Takeda Pharmaceutical Company (NYSE:TAK) has announced positive topline results from its two pivotal Phase 3 trials evaluating zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.

US stocks slid after delayed shutdown-era jobs data showed rising unemployment, while bitcoin climbed in a fresh sign of its growing divergence from traditional markets.

Ripple is celebrating the rapid ascent of its RLUSD stablecoin into the top tier of regulated USD tokens, underscoring strong institutional adoption, regulatory alignment and growing global integration.

Former Alameda Research chief executive Caroline Ellison has been transferred from federal prison to a reentry facility ahead of an early release, highlighting her cooperation in the FTX case and renewed public attention on the exchange’s collapse.

VYNE Therapeutics (NASDAQ:VYNE) and Yarrow Bioscience have entered into a definitive all-stock merger agreement, with the combined company expected to operate under the name Yarrow Bioscience and trade on Nasdaq under the ticker YARW.

ABM Industries (NYSE:ABM) reported a fiscal fourth-quarter net income of $34.8 million, or 56 cents per share, recovering from a loss in the same period last year.

However, the company’s adjusted earnings, which exclude restructuring costs and expenses related to mergers and acquisitions, were 88 cents per share, missing Wall Street expectations.

General Mills (NYSE:GIS) reported its second-quarter results for the fiscal year 2025, showing a 7 percent decrease in net sales to $4.9 billion

Processa Pharmaceuticals (NASDAQ:PCSA) provided a Phase 2 clinical update for its combination therapy, NGC-Cap (PCS6422 + capecitabine), on December 17, 2025.

Vistagen (NASDAQ:VTGN) announced disappointing results from its PALISADE-3 Phase 3 clinical trial of intranasal fasedienol, a treatment for social anxiety disorder.

The study failed to meet its primary endpoint, which was based on the change from baseline in the Subjective Units of Distress Scale (SUDS).

SCHMID Group (NASDAQ:SHMD) reported its unaudited H1 2025 financial results, revealing a significant decline in revenue to €16.9 million, compared to €29.7 million in the same period a year earlier.

Toro Co. (NYSE:TTC) reported a profit of $73 million for its fiscal fourth quarter, or 74 cents per share, beating Wall Street expectations.

Traws Pharma (NASDAQ:TRAW) reported promising interim results from its Phase 2 trial of ratutrelvir, a ritonavir-free Mpro inhibitor, in the treatment of COVID-19.

The oral treatment, administered at a 600 mg once-daily dose for 10 days, was compared against PAXLOVID™ in a randomized, open-label study involving 37 patients—25 receiving ratutrelvir and 12 receiving PAXLOVID™.

Dyadic (NASDAQ:DYAI) has expanded its strategic collaboration with Fermbox Bio to enhance the manufacturing, commercialization, and dual-sourcing of animal-free proteins and enzymes developed by Dyadic.

NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.

Cytokinetics (NASDAQ:CYTK) announced that its drug MYQORZO (aficamten) has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adults with NYHA class II-III obstructive hypertrophic cardiomyopathy.

Spire Global (NYSE:SPIR), a leading satellite data provider, reported a revenue decline for the third quarter of 2025, posting $12.7 million in sales, a drop from the same period last year.